Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
RESPONSE BIOMEDICAL CORP (RBM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/15/2016 |
8-K
| Form 8-K - Current report |
| 08/16/2016 |
8-K
| Quarterly results |
| 05/19/2016 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corp. Announces First Quarter 2016 Financial Results VANCOUVER, British Columbia – May 16, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2015, and 2016 negative Adjusted EBITDA of $, compared with a negative Adjusted EBITDA of $ in 2015. “Sales in China in the first quarter of 2016 continued to be a challenge for us. We were successful in increasing non-China sales by 16%, improving gross margin by 10 percentage points and reducing operating costs by 15% thereby reducing our Adjusted EBITDA l..." |
|
| 03/23/2016 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results VANCOUVER, British Columbia – March 21, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2014, and 2015 Adjusted EBITDA of $822,000, compared with a negative Adjusted EBITDA of $ in 2014. “We are pleased to report our first full year of Adjusted EBITDA profitable growth with a 40% increase to $15.4 million in total revenue in 2015 - $3.4 million in Joinstar collaboration revenue and $12.0 million in product sales. This..." |
|
| 08/13/2013 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corp. Announces 2013 Second Quarter Financial Results VANCOUVER, British Columbia – August 13, 2013 - Response Biomedical Corp. today reported financial results for the quarter and six months ended June 30, 2013. The Company reported sales of $2.7 million in the second quarter of 2013, a 10% decline from second quarter, 2012. The Company’s gross margin increased 3.7 percentage points versus Q2, 2012, growing from 37.9% to 41.6%. Operating expenses declined 19% to $2.1M this quarter versus last year. GAAP net income of 2013 was $3.3 million, up 40% versus the same period last year. Adjusted Net Loss, which excludes the non-cash impact of the warrant liability, decreased to $1.1 million compared to $1.6 million in the comparative quarter last year. The Company’s adjusted..." |
|
| 11/15/2012 |
8-K
| Quarterly results |
| 05/08/2012 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corporation Announces First Quarter 2012 Financial Results VANCOUVER, British Columbia – May 7, 2012 - Response Biomedical Corporation today reported financial results for the three months ended March 31, 2012. Financial results for the period ended March 31, 2012 · Product sales of $2.98 million for the three months ended March 31, 2012, compared to $2.02 million for the three months ended March 31, 2011. o Cardiovascular sales have increased to $2.68 million during the three months ended March 31, 2012, compared to $1.53 million in the comparative period in 2011. An increase in sales to China was the primary driver of this growth. o Infectious disease, Bio-defense, and Vector Infectious Disease sales decreased to $0.30 million during the three months ended March 31, 2..." |
|
| 03/28/2012 |
8-K
| Quarterly results |
|
|